Skip to main content
Tech.euFundingExplorerBeta

Rigontec

RNA-based immunotherapeutics for the treatment of cancer and viral diseases

Rigontec has raised €28M across 3 funding rounds from 8 investors, most recently a Series A round in Sep 2016. Based in Bonn, Germany; founded 2014; active in Healthtech. Data as of 28 Oct 2026.

Bonn, GermanyFounded 2014rigontec.de ↗
Healthtech
← All companies
Total raised
€28M
€27,850,000
Funding rounds
3
Investors
8
distinct backers
Active since
2014-10
latest 2016-09

Funding by year

EUR raised per year
Rigontec — funding by year — interactive chart.
Data table
Rigontec — funding by year
2014€9.4M
2015€4.8M
2016€14M

Signals

High confidence
Raise-next likelihood10
base rate 44% for Series A
  • ▼ Dormant (no round in 3+ cohort gaps)
  • ▲ Up-round momentum
Exit likelihood10
base rate 11% (2+ rounds)
  • ▼ No recent equity round (debt-only or quiet)

Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

3 rounds
DateStageAmountInvestors
2016-09-01Series A€14MBoehringer Ingelheim Venture Fund,Forbion,High-Tech Gründerfonds (HTGF),MP Healthcare Venture Management,NRW.BANK,Sunstone Capital+1 moreView deal →
2015-03-01Series A€4.8MBoehringer Ingelheim Venture Fund,Forbion,High-Tech Gründerfonds (HTGF),NRW.BANK,Sunstone Capital,Wellington PartnersView deal →
2014-10-01Series A€9.4MBoehringer Ingelheim Venture Fund,High-Tech Gründerfonds (HTGF),NRW.BANK,Wellington PartnersView deal →

Investors

8
Boehringer Ingelheim Venture FundForbionHigh-Tech Gründerfonds (HTGF)MP Healthcare Venture ManagementNRW.BANKSunstone CapitalWellington Partners

Related news

Similar companies

same sector or country

Global coverage: FundingData